VXRT
Vaxart, Inc.
0.88
+
0.02
2.87%
2 x 0.85
8 x 0.88
bid
ask
5 @ 04:00 PM
0.88+0.00 (0.49%)
![](/assets/images/down.png)
![](/assets/images/up.png)
sentiment
0.85
day range
0.89
0.52
52 week range
1.54
Prev Close0.86
Open0.85
Low0.85
High0.89
Volume876.25K
Avg. Volume4.68M
Market Cap200.28M
Inst. Own18.13%
Beta0.67
Short Ratio7.89
Div & Yield0.00 /
EPS-0.45
P/E0.00
1yr Target4.83
50day MA0.72
200day MA0.85
^DJI
Dow Jones Industrial Average
40755.80
04:45 PM
-
219.20
0.53%
^IXIC
NASDAQ Composite
17127.70
05:15 PM
+
43.40
0.25%
^GSPC
S&P 500
5503.41
04:45 PM
-
16.66
0.30%
Day Gain | ||
Gain | ||
Market Val | ||
Costs | ||
Cash | ||
Portfolio | ||
Realized | ||
Dividend |
News
...
Holdings of Vaxart Inc (VXRT) are aligned with the stars | news.google.com • |
When Would Be The Best Time To Buy TeraWulf Inc (NASDAQ: WULF) Stock? | news.google.com • |
What Do Wall Street Analysts Think About Vaxart Inc (NASDAQ: VXRT) Stock? | news.google.com • |
Vaxart Inc (VXRT) stock analysis: A comprehensive overview | news.google.com • |
Vaxart (NASDAQ:VXRT) Share Price Crosses Below Two Hundred Day Moving Average of $0.88 | news.google.com • |
Quarterly Snapshot: Quick and Current Ratios for Vaxart Inc (VXRT) | news.google.com • |
Profile
...
Vaxart, Inc., a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions. It has a license agreement with Altesa Biosciences, Inc. to develop and commercialize Vapendavir, a capsid-binding broad-spectrum antiviral. Vaxart, Inc. is headquartered in South San Francisco, California.
Earning
...
Date | For | Estimate | Reported | Surprise | surprise % |
---|---|---|---|---|---|
2024-08-08 | 2024-06 | 0.03 | -0.09 | -0.12 | -400.00% |
2024-05-13 | 2024-03 | -0.16 | -0.14 | 0.02 | 12.50% |
2024-03-14 | 2023-12 | -0.15 | -0.12 | 0.03 | 20.00% |
2023-11-02 | 2023-09 | -0.18 | -0.11 | 0.07 | 38.89% |
2023-08-03 | 2023-06 | -0.19 | -0.16 | 0.03 | 15.79% |
2023-05-04 | 2023-03 | -0.19 | -0.19 | N/A | N/A |
Upgrade / Downgrade
...
Date | Firm | Action | From | To |
---|---|---|---|---|
2023-09-06 | Cantor Fitzgerald | Upgrade | Overweight | Overweight |
2023-08-06 | Cantor Fitzgerald | Upgrade | Overweight | Overweight |
2022-12-18 | B. Riley Securities | Upgrade | Neutral | |
2022-09-01 | Cantor Fitzgerald | Upgrade | Overweight | |
2022-05-18 | B. Riley Securities | Upgrade | Neutral | |
2021-11-01 | Cantor Fitzgerald | Upgrade | Overweight |
Insider Holder
...
Date | Name | Relation | Quantity | Description |
---|---|---|---|---|
2024-03-17 | BERG EDWARD B | General Counsel | 270.71K | Stock Award(Grant) |
2024-03-17 | CUMMINGS JAMES F. | Officer | 330.09K | Stock Award(Grant) |
2024-06-10 | FINNEY MICHAEL J | Director | 686.84K | Stock Award(Grant) |
2024-06-10 | HERON ELAINE J | Director | 40.57K | Stock Award(Grant) |
2024-03-17 | LEE PHILLIP E. | Chief Financial Officer | 241.81K | Stock Award(Grant) |
2024-03-17 | LO STEVEN | Chief Executive Officer | 250.00K | Stock Award(Grant) |
Institution Ownership
...
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Cantor Fitzgerald, L. P. | 7.09M | 5.17M | 4.66% |
2023-06-29 | Vanguard Group Inc | 6.89M | 5.03M | 4.54% |
2023-06-29 | Millennium Management Llc | 2.14M | 1.56M | 1.41% |
2023-06-29 | Blackrock Inc. | 1.93M | 1.41M | 1.27% |
2023-06-29 | Geode Capital Management, LLC | 1.57M | 1.15M | 1.03% |
2023-06-29 | Renaissance Technologies, LLC | 792.01K | 578.16K | 0.52% |
Fund Ownership
...
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Vanguard Total Stock Market Index Fund | 4.07M | 2.97M | 2.68% |
2023-06-29 | Vanguard Extended Market Index Fund | 1.77M | 1.29M | 1.16% |
2023-05-30 | Fidelity Extended Market Index Fund | 631.59K | 770.54K | 0.42% |
2023-05-30 | Schwab Strategic Tr-Schwab U.S. Small Cap ETF | 559.90K | 683.08K | 0.37% |
2023-05-30 | Vanguard Health Care Index Fund | 480.63K | 586.37K | 0.32% |
2023-06-29 | Vanguard Horizon Fund-Strategic Small-Cap Equity Fund | 361.97K | 264.24K | 0.24% |
Dividend
...
Dividend | Date |
---|---|
0.1847 | 2012-11-09 |
Split
...
Split | Date |
---|---|
1 : 11 | 2018-02-14 |
0.16667 : 1 | 2012-11-09 |
This topic has been deleted. Only users with topic management privileges can see it.
-
Holdings of Vaxart Inc (VXRT) are aligned with the stars
news.google.com • -
When Would Be The Best Time To Buy TeraWulf Inc (NASDAQ: WULF) Stock?
news.google.com • -
Vaxart Inc (VXRT) stock analysis: A comprehensive overview
news.google.com • -
Quarterly Snapshot: Quick and Current Ratios for Vaxart Inc (VXRT)
news.google.com • -
Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com • -
Vaxart, Inc. (VXRT) Q2 2024 Earnings Call Transcript
seekingalpha.com • -
Vaxart Inc: Asymmetric Risk-Reward Opportunity Following BARDA Funding
seekingalpha.com • -
Vaxart Provides Business Update
globenewswire.com • -
Vaxart Announces $40 Million Underwritten Offering of Common Stock
globenewswire.com • -
Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com • -
Vaxart, Inc. (VXRT) Q1 2024 Earnings Call Transcript
seekingalpha.com • -
Vaxart Provides Business Update and Reports First Quarter 2024 Financial Results
globenewswire.com • -
Vaxart to Present at World Vaccine Congress Washington 2024 on April 3
globenewswire.com • -
Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com • -
Vaxart, Inc. (VXRT) Q4 2023 Earnings Call Transcript
seekingalpha.com • -
Vaxart Provides Business Update and Reports Full Year 2023 Financial Results
globenewswire.com •